Ferrer and Medivir Enter Agreement for Commercializing a New Treatment for
Agitation Associated with Schizophrenia and Bipolar Disease in the Nordics
HUDDINGE, Sweden -- September 18, 2013
Medivir AB (Nasdaq OMX: MVIR) (STO:MVIR-B) and Ferrer today announced that
they have entered a license and distribution agreement for the
commercialization of ADASUVE® (Staccato® Loxapine) in the Nordic region. In
Europe, ADASUVE is approved for the treatment of mild to moderate agitation of
patients with schizophrenia or bipolar disease.
Under the terms of the agreement, Ferrer grants to Medivir the exclusive
rights to promote, market, sell and distribute ADASUVE in the Nordic region –
including Denmark, Finland, Norway, Iceland and Sweden. ADASUVE is a hand-held
inhaler designed to deliver the drug to the deep lung, providing rapid
systemic delivery in a simple, non-invasive manner. Medivir thus becomes the
exclusive supplier of this new treatment therapy for the treatment of mild to
moderate agitation of patients with schizophrenia or bipolar disease. In
return, Ferrer will receive an up-front payment upon signature, and milestone
payments conditional upon cumulative sales performance.
“This licensing agreement is in line with our strategy to add new products to
our Nordic portfolio. ADASUVE is the first addition to the portfolio, which
now consists of 16 prescription pharmaceuticals” said Mr Maris Hartmanis,
Medivir’s CEO. He added, “ADASUVE is a very interesting product based on a
novel administration technology addressing an unmet medical need, which
expands our present offering to psychiatrists, Lithionit. We are excited about
having secured the commercial rights to ADASUVE for the Nordic region and the
partnership with Ferrer”.
“We belive that ADASUVE will be a breakthrough in the treatment of agitation
and is going to change the way in which the condition is viewed by both
healthcare professionals and patients”, said Mr. Antoni Villaró, Chief
Operating Officer of Ferrer. He added, “We are excited to be introducing
ADASUVE to the European psychiatric and hospital treatment community as
ADASUVE is now available in Germany, and thank to this agreement soon in the
“We take pride in developing a strong network of partners that, along with our
commercial resources, contribute to bring to the market innovative products
aimed at underserved conditions”, said Mr. Pedro de Antonio, Ferrer’s
International Director for Europe, Asia, Middle East and Africa.
Agitation is a severe, disruptive, and morbid complication suffered by
patients with schizophrenia and bipolar disorders.
Patients who experience agitation describe feeling an inner distress that
progresses to an outwardly apparent dysfunctional state manifested by verbal
abuse, hostility, difficulty controlling impulses, uncooperative behavior and
increased potential for violence. While the time after which agitation
requires treatment can be variable (minutes, hours or days), once the patient
escalates to this point, urgent treatment is always required.
Currently, the standard of care in the treatment of acute agitation is
pharmacological tranquilization with antipsychotics, sometimes combined with
ADASUVE, an inhaled formulation of the antipsychotic drug loxapine, begins to
control patients’ agitation in less than 10 minutes, intercepting the onset of
agitation in a noninvasive manner.
About ADASUVE (Staccato Loxapine)
ADASUVE combines the proprietary Staccato system with loxapine, an
antipsychotic medicinal product. The Staccato system is a hand-held inhaler
that delivers a drug aerosol to the deep lung resulting in intravenous-like
pharmacokinetics and rapid systemic effects.
ADASUVE has been approved for marketing in the EU by the European Commission.
For more information about ADASUVE, including the Summary of Product
Characteristics and Patient Information Leaflet approved in the EU please
Medivir is an emerging research-based pharmaceutical company focused on
infectious diseases. Medivir has world class expertise in polymerase and
protease drug targets and drug development which has resulted in a strong
infectious disease R&D portfolio. The Company’s key pipeline asset is
simeprevir, a novel protease inhibitor in late phase III clinical development
for hepatitis C that is being developed in collaboration with Janssen R&D
Medivir has also a broad product portfolio with prescription pharmaceuticals
in the Nordics.
For more information, visit www.medivir.com
Ferrer is a privately-held European R&D-based pharmaceutical company
headquartered in Barcelona. It is active in the pharmaceutical, health, fine
chemicals and food sectors in Europe, Latin America, Africa, the Middle East,
Asia and the United States. In total, Ferrer's human healthcare products are
commercialized in more than 90 countries, through 23 international affiliates
(including joint ventures) and 70 partners and distributors.
Ferrer carries out activities throughout the full pharmaceutical value chain,
from R&D to international marketing, including fine chemical development and
the manufacturing of both raw materials and finished pharmaceuticals. Its
research centers in Spain and Germany, and manufacturing sites in Europe and
Latin America cover the pharmaceutical, diagnostics, vaccine, fine chemical,
food and feed sectors.
Ferrer holds the commercial rights for ADASUVE in Europe, Latin America,
Russia and the Commonwealth of Independent States countries. ADASUVE® and
Staccato® are registered trademarks of Alexza Pharmaceuticals, Inc.
For more information, visit www.ferrergrupo.com
This information was brought to you by Cision http://news.cision.com
Mobile: +46 (0)708 537 292
+34 93 6000 3860
For partnering information:
+34 93600 3867
Press spacebar to pause and continue. Press esc to stop.